Lb Pharmaceuticals announced it raised $111 Million in an amended filing from an offering of $111 Million

Company

Location

About

LB Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of schizophrenia. Our lead drug candidate is a second-generation antipsychotic and a potential first-in-class benzamide to enter the U.S. market. With robust clinical development underway and a focus on long-term patient outcomes, we aim to set a new standard of care for neuropsychiatric conditions.